Synthesis and anticancer activity of long-chain isonicotinic ester ligand-containing arene ruthenium complexes and nanoparticles


Autoria(s): Süss-Fink G.; Khan F-A.; Juillerat-Jeanneret L.; Dyson P.J.; Renfrew A.K.
Data(s)

01/04/2010

Resumo

Arene ruthenium complexes containing long-chain N-ligands L1 = NC5H4-4-COO-C6H4-4-O-(CH2)9-CH3 or L2 = NC5H4-4-COO-(CH2)10-O-C6H4-4-COO-C6H4-4-C6H4-4-CN derived from isonicotinic acid, of the type [(arene)Ru(L)Cl2] (arene = C6H6, L = L1: 1; arene = p-MeC6H4Pr i , L = L1: 2; arene = C6Me6, L = L1: 3; arene = C6H6, L = L2: 4; arene = p-MeC6H4Pr i , L = L2: 5; arene = C6Me6, L = L2: 6) have been synthesized from the corresponding [(arene)RuCl2]2 precursor with the long-chain N-ligand L in dichloromethane. Ruthenium nanoparticles stabilized by L1 have been prepared by the solvent-free reduction of 1 with hydrogen or by reducing [(arene)Ru(H2O)3]SO4 in ethanol in the presence of L1 with hydrogen. These complexes and nanoparticles show a high anticancer activity towards human ovarian cell lines, the highest cytotoxicity being obtained for complex 2 (IC50 = 2 μM for A2780 and 7 μM for A2780cisR)

Identificador

https://serval.unil.ch/?id=serval:BIB_624C20BDFB9B

isbn:1040-7278

doi:10.1007/s10876-010-0298-6

isiid:000282099600007

Idioma(s)

en

Fonte

Journal of cluster science, vol. 21, pp. 313-324

Palavras-Chave #ruthenium nanoparticles; anticancer drugs; bioorganometallic chemistry; isonicotinic ester ligands; arene ruthenium complexes
Tipo

info:eu-repo/semantics/article

article